CLN-619

DRUG2 trials

Sponsors

Cullinan Therapeutics Inc.

Conditions

Advanced Solid TumorMultiple MyelomaNSCLC

Phase 1

A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Active, not recruitingNCT05117476

Cullinan Therapeutics Inc.Advanced Solid Tumor, NSCLC

Start: 2021-10-29End: 2026-06-30Target: 440Updated: 2025-11-24

A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

Active, not recruitingNCT06381141

Cullinan Therapeutics Inc.Multiple Myeloma

Start: 2024-09-03End: 2027-03-31Target: 30Updated: 2025-09-18

Related Papers

Cln-619 (anti-MICA/B antibody) alone and in combination with pembrolizumab (P) for advanced solid tumors: Updated results of a Ph1 study.

Journal of Clinical Oncology2024-06-011 citations

Abstract 5297: CLN-619, a clinical stage MICA/B-specific hIgG1 monoclonal antibody, engages multiple immune effector cells to promote anti-tumor activity

Cancer Research2024-03-221 citations

194 Characterization of the pharmacodynamic activity of CLN-619, an anti-MICA/B monoclonal antibody, in patients from an ongoing Phase 1 trial

Regular and Young Investigator Award Abstracts2023-10-31

A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.

Journal of Clinical Oncology2023-06-011 citations

1395 CLN 619 a clinical stage MICA B specific IgG1 antibody which restores the MICA B-NKG2D axis requires Fc function for potent anti-tumor activity

Regular and Young Investigator Award Abstracts2022-11-011 citations

A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of CLN-619 (anti-MICA/MICB antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.

Journal of Clinical Oncology2022-06-011 citations